PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose in heavily pre-treated patients with relapsed or refractory multiple myeloma, according to early data from an ongoing Phase 1/2 trial. “The very high response rate observed with PF-06863135, coupled with manageable safety and the convenience of subcutaneous [under the skin] administration, underscores the potential impact this medicine may have,” Jeff Settleman,…
You must be logged in to read/download the full post.
The post Bispecific Antibody Shows Early, Promising Responses in Trial appeared first on BioNewsFeeds.